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Background: Published models predicting nasal colonization with Methicillin-resistant Staphylococcus aureus
among hospital admissions predominantly focus on separation of carriers from non-carriers and are frequently
evaluated using measures of discrimination. In contrast, accurate estimation of carriage probability, which may
inform decisions regarding treatment and infection control, is rarely assessed. Furthermore, no published models
adjust for MRSA prevalence.
Methods: Using logistic regression, a scoring system (values from 0 to 200) predicting nasal carriage of MRSA was
created using a derivation cohort of 3091 individuals admitted to a European tertiary referral center between July
2007 and March 2008. The expected positive predictive value of a rapid diagnostic test (GeneOhm, Becton &
Dickinson Co.) was modeled using non-linear regression according to score. Models were validated on a second
cohort from the same hospital consisting of 2043 patients admitted between August 2008 and January 2012. Our
suggested correction score for prevalence was proportional to the log-transformed odds ratio between cohorts.
Calibration before and after correction, i.e. accurate classification into arbitrary strata, was assessed with the Hosmer-
Lemeshow-Test.
Results: Treating culture as reference, the rapid diagnostic test had positive predictive values of 64.8% and 54.0% in
derivation and internal validation corhorts with prevalences of 2.3% and 1.7%, respectively. In addition to low
prevalence, low positive predictive values were due to high proportion (> 66%) of mecA-negative Staphylococcus
aureus among false positive results. Age, nursing home residence, admission through the medical emergency
department, and ICD-10-GM admission diagnoses starting with “A” or “J” were associated with MRSA carriage and
were thus included in the scoring system, which showed good calibration in predicting probability of carriage and
the rapid diagnostic test’s expected positive predictive value. Calibration for both probability of carriage and
expected positive predictive value in the internal validation cohort was improved by applying the correction score.
Conclusions: Given a set of patient parameters, the presented models accurately predict a) probability of nasal
carriage of MRSA and b) a rapid diagnostic test’s expected positive predictive value. While the former can inform
decisions regarding empiric antibiotic treatment and infection control, the latter can influence choice of screening
method.
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Staphylococcus aureus can cause a wide range of hospital
and community associated infections including endocar-
ditis, pneumonia, osteomyelitis, and wound infections.
In contrast to methicillin-susceptible S. aureus (MSSA),
infections by methicillin-resistant S. aureus (MRSA)
were described as causing increased length of hospital
stay [1], higher lethality [2], and delayed resolution of
ventilator-associated pneumonia despite appropriate
antibiotic treatment [3]. In the healthcare setting, yearly
over 150,000 individuals are estimated to suffer from
infections by MRSA in the European Union, with attrib-
utable costs for hospitals exceeding 380 million Euro [4].
In the United States, over 90,000 invasive infections are
estimated to occur per year, translating to an incidence
rate of over 30/100,000 [5].
The spectrum of possible control measures aimed at
curbing spread of MRSA include screening of patients for
nasal carriage on admission, isolation of case patients,
decolonization at the end of hospitalization, screening of
contacts and hospital staff for colonization, ward closures
in case of exuberant nosocomial transmissions [6], and
antibiotic prescribing interventions [7]. Several countries
including the Netherlands [8] and, since 2006, the UK [9]
recommend screening of hospital admissions. A meta-
analysis focusing on the use of rapid molecular tests
showed that screening at admission reduced incidence
rates of bacteremia, yet not surgical-site infections by
MRSA [10].
Many models predicting carriage of MRSA focus on
discrimination [11-14], i.e. the ability to separate
individuals colonized with MRSA from the rest by giving
a yes/no answer for a given set of patient characteristics.
A reason for this may be the interest of researchers to
restrict screening efforts to a subset of individuals with
high risk, thereby saving diagnostic resources. This ap-
proach is recommended in low prevalence areas [15]
and has been adopted in countries including the Nether-
lands [8]. Nevertheless, sensitivities of prediction tools in
separating carriers from non-carriers are moderate at
best: e.g. Robicsek et al. presented models with compar-
ably good discriminatory ability, which nevertheless
missed at least 32% of carriers within the validation co-
hort even if 30% of admissions were screened [11]. Simi-
larly, other models would have missed approximately
20% [14] and 14% [12] of carriers even if larger
proportions (> 62%) of admissions had been screened,
respectively. Despite limited discriminatory ability and
versatility of tools focusing on providing binary results
(by suggesting who to screen or not to screen), very few
published models address calibration, i.e. the ability to
predict individual probability of carriage. One example is
a model by Sax et al., which, however, assessed calibra-
tion only across three risk strata [13].Currently, no published models adjust for the effect of
prevalence. Even though formally not affecting overall
measures of discrimination such as AUC in ROC-
analysis, prevalence affects cutoff and threshold values
extractable from predictive models, and thus accurate
classification into two or more strata across settings with
different rates of MRSA. In addition, it has a profound
impact on the positive predictive values (PPV) of rapid
molecular screening tests. Multiple reports using tests
based on the amplification of fragments spanning the 30
end of SCCmec and the 50 end of orfX document low
PPVs between 31% to 65% in settings with prevalence
below 5%, regardless of the test’s producer [16-18].
In the present study we derive and internally validate a
scoring system able to predict the probability of nasal MRSA
carriage and the expected PPV of a rapid diagnostic test in
individuals admitted to a European tertiary referral center.
Furthermore, we propose and internally validate a correction
method for prevalence differing from our derivation cohort,
thus facilitating use of the presented models in settings with
different or changing rates of MRSA.
Methods
Patient cohorts
We used two cohorts of patients admitted to the
University Hospital of Wuerzburg, which is a tertiary
referral center with approximately 50,000 inpatient
admissions per year. The first cohort (derivation cohort,
DC) consisted of a study approved by the Ethics Commit-
tee of the Medical Faculty of the University of Würzburg
(reference no. 62/07; applicant: UV) aiming to estimate the
prevalence of MRSA nasal carriage in admissions to 13
wards and admissions passing through the medical emer-
gency department between July 2007 and March 2008.
Wards were selected to ensure a representation of surgical,
medical, intensive care, and non-intensive care patients.
All swabbed individuals or their legal guardians gave verbal
consent to being tested; this policy was additionally
approved by the legal department of the University Hos-
pital of Wuerzburg. Individuals were included into this co-
hort if they were at least 18 years old and a rapid
molecular test had been performed from a nasal swab no
later than 2 days after admission. Of patients admitted
more than once, only data and test results pertaining to
the first admission were considered. In total, 3091 of 5039
eligible admitted individuals (61.3%) were included. Reasons
for moderate coverage encompassed, besides failure to ad-
minister the test (1488 of 5039, 29.5%), failure to swab the
nose (310, 6.2%), and failure to test within 48 hours after ad-
mission (150, 3.0%). The age range was 18 to 102 (interquar-
tile range: 46 to 75); mean and median ages were 59.7 and
64.0 years, respectively. Men slightly prevailed in the cohort
with 54.9%. As one of the authors requested the Ethics
committee’s vote (UV) and two authors (UV, JE) are part of
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mentation of risk based screening, no additional permission
was necessary to access and use data from the derivation co-
hort. The second cohort (internal validation cohort, IVC)
consisted of a convenience sample of admissions to units F,
K, L, and M (Table 1), which voluntarily continued non-
selective screening with the rapid molecular test after March
2008. As above, all patients or their legal guardians
consented to being tested for the presence of MRSA. For this
cohort, no separate approval by the Ethics committee was
sought, because it consisted of routinely collected data from
the laboratory of the Institute for Hygiene and Microbiology
and the hospital information system required for the imple-
mentation of a German national recommendation to per-
form risk based screening [19]. In order to comply with
these recommendations, above wards pilot-tested an elec-
tronic nursing history system at various intervals between
August 2008 and January 2012, which also recorded infor-
mation regarding nursing home referral. The electronic nurs-
ing history was available for 2978 of 6449 admissions ≥
18 years old within this period; 2509 of these were tested
with nasal swabs, yet 466 were excluded because swabs were
performed > 48 hours after admission. Thus, 2043 patients
(68.6% of individuals with electronic nursing history) were
included into IVC. Analogous to DC, only data from the first
admission were included into IVC for patients admitted
more than once. The age range in IVC was 18 to 99 years
(interquartile range: 56 to 78); mean and median ages were
higher than in DC with 65.8 and 70.0 years, respectively
(p < 0.001, Mann–Whitney test). The proportion of men
in IVC was 54.1% and not significantly different from DCTable 1 List of units participating in the derivation cohort
(DC) between July 2007 and March 2008
Unit(s) Specialty ICU MRSA
neg
MRSA
pos
Prevalence
A Medicine 191 9 4,5
B, D Surgery 501 10 2,0
C Surgery + 134 4 2,9
E Urology 308 1 0,3
F Maxillofacial
Surgery
477 16 3,2
G, H, I,
J
Dermatology 409 9 2,2
K Neurology 358 3 0,8
L Neurology + 156 3 1,9
M Anesthesiology + 162 0 0,0
N Emergency
Medicine
323 17 5,0
All 3019 72 2,3
Units also providing patients for the validation cohort between Auguts 2008
and January 2012 are bold italic. ICU: intensive care unit.(p = 0.586, Chi-squared test). Only anonymized data from
DC and IVC were stored and used for analysis at all times.
Acquisition of data
For DC, patient related data including age, sex, referral
from another hospital, 10th version of the German Modi-
fication of the International Classification of Diseases’
(ICD-10-GM) code of admission diagnosis, date of ad-
mission, ward, and admission via medical emergency de-
partment were extracted prospectively from the hospital
information system. Information regarding nursing
home referral was collected prospectively using a paper
form attached to the laboratory request slip accompany-
ing the nasal swab. For IVC, data were extracted retro-
spectively from the hospital information system and the
new electronic nursing history system.
Rapid diagnostic test and confirmation of methicillin
resistance
The GeneOhm test (BDGO, Becton Dickinson GmbH,
Heidelberg, Germany) was used to detect MRSA in nasal
swabs. All tests were compared to culture, which was
treated as the reference standard. Thus, after use for
rapid testing, sampling buffers were overlaid with brain-
heart infusion (BHI) broth, incubated at 36°C overnight,
and plated on Columbia agar with 5% sheep blood,
DifcoTM Baird-Parker (Becton Dickinson GmbH), and
CHROMagarTM MRSA medium (CHROMagar, Paris,
France). Solid media were subsequently incubated for
48 h at 36°C with 5% CO2. Mauve colonies on
Chromagar, or colonies suggestive of S. aureus on blood
or Baird-Parker medium were isolated and confirmed
with Vitek II (bioMérieux, Nürtingen, Germany) using
GP and AST-P592 cards for species identification and
antimicrobial susceptibility testing, respectively. Presence
of the mecA gene was confirmed by PCR using primers
MecA1 and MecA2 published previously [20]. Each
rapid test result was grouped into one of five mutually
exclusive categories: a) true positive (tp), if a positive test
result was confirmed by culture of MRSA; b) deletion
variant (dv), if a positive test result was followed by cul-
ture of methicillin-susceptible S. aureus; c) not culturally
confirmed (nc), if a positive test result was not followed
by growth of S. aureus (i.e. positive result, but not “dv”
and not “tp”); d) false negative (fn), if a negative result
was followed by growth of MRSA; and e) true negative
(tn), if a negative result was not followed by growth of
MRSA. Categories “dv” and “nc” were both regarded as
false positives (fp). As only a single result was considered
per admission even if multiple rapid tests had been
processed, inclusion of results was prioritized according
to the hierarchy tp > dv > fn > nc > tn. For patients ad-
mitted more than once, data from the first admission
only were included into analyses.
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Cultural results were treated as the gold standard for the
estimation of the rapid diagnostic test’s (RDT) perform-
ance parameters, i.e. specificity (Sp), sensitivity (Sn),
positive predictive value (PPV), and negative predictive
value (NPV). Ninety-five percent confidence intervals
for the test’s performance parameters were calculated as-
suming a binomial distribution of estimates. Differences
in proportions and performance parameters between
cohorts were assessed with the Fisher’s Exact Test.
Multivariate logistic regression testing association of
covariates, which were all treated as exposures, with car-
rier status was performed with the program R [21].
Predictors were removed from the model, unless this
significantly increased deviance of the model. Similarly,
levels of categorical variables (e.g. admission diagnoses)
were allowed to aggregate, if this did not significantly in-
crease deviance of the model. In order to facilitate the
model’s use in the clinical setting, log-transformed odds
were translated to scores ranging from 0 to 200. Score
translation and ROC analysis was accomplished using
the R-package “rms” [22]. Briefly, the score (denoted as
S) represents a linear transformation of fitted log-
transformed odds (denoted as L) of the form S=a+b L,
whereby parameters a and b are chosen to ensure opti-
mal representation of L on a scale ranging from 0 to
200; transformation of S to individual probability of car-
riage p was carried out using the formula p ¼
e
aS
b þ 1
 1
. Prediction of the RDT’s positive predictive
value (PPV) from the score was performed using non-
linear regression based on the function PPV ¼
f
oþ 1
 1
, where odds o ¼ eSab , and f, equaling 1SpSn , was
the parameter to be estimated. The suggested correction
score Sc added according to prevalence was computed
using the formula Sc = log(OR) · b; here, OR represents
the odds ratio between the new population being
corrected for and the derivation cohort, calculated as
OR ¼ oddsnew0:0238 ; moreover, b is the slope of the linear trans-
formation between log-transformed odds and score (see
above). Goodness-of-fit of the predictive models was
assessed with the Hosmer-Lemeshow-Test [23].Results
Performance of the rapid diagnostic test
Of 3091 tests considered in the first cohort (DC), 70, 38,
2981, and 2 were categorized as true positive, false posi-
tive, true negative, and false negative, respectively. Preva-
lence of culturally confirmed MRSA nasal carriage
within DC was 2.3% (Table 1). Of 38 false positives, 25
(65.8%) were due to methicillin susceptible S. aureusthat lacked mecA, as shown by PCR. Retesting of these
strains, designated “deletion variants”, with BDGO
yielded positive results, suggesting remain of DNA span-
ning a part of the SCCmec cassette and orfX. The test’s
sensitivity, specificity, PPV, and NPV in DC was 97.2%
(95% confidence interval 90.3% to 99.7%), 98.7% (98.2%
to 99.1%), 64.8% (55.0 to 73.8%), and 99.9% (99.8% to
100%), respectively. In the second cohort (IVC) 34, 29,
1980, and 0 were true positive, false positive, true nega-
tive, and false negative, respectively; MRSA prevalence
in IVC was 1.7%. Of 29 false positive results, 23 (79.3%)
were due to deletion variants. Sensitivity, specificity,
PPV, and NPV in IVC were 100% (89.7% to 100%),
98.6% (97.9% to 99.0%), 54.0% (40.9% to 66.6%), and
100% (99.8% to 100%), respectively. Differences of per-
formance parameters were not significantly different be-
tween cohorts according to Fisher’s Exact Test. Also, the
difference in prevalence between DC and IVC was not
statistically significant (p = 0.109, Fisher’s Exact Test).
Prediction of nasal carriage of MRSA
Due to the linear relationship of log-transformed odds
of nasal carriage and age within DC (Figure 1), we
treated age as a continuous variable in our models. We
evaluated exposures including age, sex, referral from an-
other hospital, referral from a nursing home, admission
via the emergency department, and the first letter of the
admission diagnosis according to ICD-10-GM. We
allowed strata of categorical variables (e.g. admission
diagnoses) to lump to simpler forms if coefficients of in-
dividual levels were similar and aggregation did not in-
crease the deviance of the model. Age, admission via
emergency department, aggregation of admission diag-
noses starting with “A” (“Certain infectious and parasitic
diseases”) or “J” (“Diseases of the respiratory system”),
and nursing home referral were significantly associated
with carrier status (Table 2). The group of admission
diagnoses starting with letters “A” or “J” comprised 40
distinct ICD-10-GM codes assigned to a subset of 84
individuals; the five most common diagnoses A46 (“Ery-
sipelas”, 18 of 84), J18.8 (“Other pneumonia, organism
unspecified”, 10/84), A41.9 (“Sepsis, unspecified”, 5/84),
J44.9 (“Chronic obstructive pulmonary disease, unspeci-
fied”, 5/84), and J32.0 (“Chronic maxillary sinusitis”, 4/
84) were found in 50% of patients (42/84) within
this group. In contrast to the average prevalence (2.3%),
rates of MRSA carriage among medical emergency
admissions, nursing home residents, and patients with
admission diagnoses starting with “A” or “J” were 5.0%
(17/340), 11.0% (11/100), and 9.5% (8/84), respectively.
Based on this model, we transformed the fitted log-
transformed odds to a score ranging from 0 to 200 using
the intercept a = 190.7 and linear coefficient b = 34.0.
The score for a patient in DC was computed by
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Figure 1 Graphical representation of the linear relationship
between age and log-transformed odds of carriage within the
derivation cohort according to univariate logistic regression.
Score
Pr
ob
ab
ilit
y 
of
 c
ar
ria
ge
 
10 20 30 40 50 60 70 80 90 100
0.00
0.02
0.04
0.06
0.08
observed
predicted
Figure 2 Fit of logistic regression model in the prediction of
carriage probability in the derivation cohort. Open circles
labeled “observed” represent probability within intervals represented
by median score. Interval limits were chosen to ensure equal
number of individuals per interval.
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22 points in case of emergency admission, 37 points, if
the patient is nursing-home resident, and 39 points, if
the admission diagnosis belonged to headings “A” or “J”
according to ICD-10-GM (Table 2). The model
approximated observed score-based probability reason-
ably well (Figure 2), as confirmed by the Hosmer-
Lemeshow-Test (χ2 = 7.9, 8 degrees of freedom,
p=0.440). Further, the model had moderate discrimin-
atory ability with an AUC of 0.693 according to ROC-
analysis.Prediction of the rapid diagnostic test’s positive
predictive value
Using non-linear regression, we fitted a function describ-
ing PPV’s dependence on specificity, sensitivity (the latter
two values merged within the parameter f), and individual
odds, whereby observed PPV was aggregated into 8
groups by score (Figure 3). The fitted parameter f was
0.0135, and thus very close to the observed quotient 1SpSn
(0.0134) within DC. The Hosmer-Lemeshow-Test on a
subset of DC with positive molecular results did not show
evidence for insufficient fit (χ2 = 9.4, 6 d.f., p=0.150).Table 2 Odds ratios (OR) from the logistic regression model w
of the probability of nasal carriage of Methicillin-resistant Sta
Variable Crude OR (95% CI)
Age 1.04 (1.02,1.05)
Nursing home 5.94 (3.02,11.67)
Admission diagnosis: A or J 4.84 (2.24,10.45)
Emergency admission 2.58 (1.48,4.5)
Pw: p-value according to the Wald-Test. An initial score for a patient is calculated by
corresponding variable is true. If prevalence differs from 2.3%, a correction score (FInternal validation and calibration
We internally validated the predictive ability of functions
translating scores into individual probability of nasal car-
riage of MRSA and the PPV of the rapid diagnostic test
(Figure 4) on a separate cohort from the same hospital
(IVC). Although the difference in prevalences between
DC and IVC did not reach statistical significance (1.7%
vs. 2.3%, p = 0.109, see above), we explored whether a
correction for this disparity resulted in a more accurate
prediction. For IVC, score correction was equivalent to
−11.7 points (Figure 5); addition of this value led to a
better graphical fit of score-based prediction (Figure 6).
This was further indicated by reduction of the χ2 value
of the Hosmer-Lemeshow-Test from the uncorrected
(χ2 = 8.1, d.f. = 8, p = 0.427) to the corrected (χ2 = 4.3, 8
d.f., p = 0.831) model, although in both cases the fit was
acceptable (demonstrated by p > 0.05). Moreover,
categorizing patients into arbitrary strata with “very low”
(≤ 1%), “low” (> 1% to ≤ 3%), “intermediate” (> 3% to ≤
6%), and “high” (> 6%) probability of carriage was only
accurately achieved with the corrected model (Table 3);
specifically, the uncorrected model classified 299
patients into the “intermediate” category, although theirith 95% confidence intervals (CI) used for the prediction
phylococcus aureus
Adjusted OR (95% CI) pW Score
1.03 (1.01,1.05) < 0.001 Age - 10
3.00 (1.45,6.19) 0.003 37
3.18 (1.39,7.28) 0.006 39
1.93 (1.08,3.47) 0.028 22
subtracting 10 from age and adding values in column “Score”, if the
igure 5) has to be added.
Score
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V
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Figure 3 Fit of non-linear regression model describing the
rapid diagnostic test’s positive predictive value depending on
the score within the derivation cohort. Full circles labeled
“observed” represent positive predictive value within intervals
represented by median score. Interval limits were chosen to ensure
equal number of positive results per interval.
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trast, the corrected model shifted 261 of “intermediate”
patients into category “low”, thus achieving accurate pre-
diction. In total, correction led to a reclassification of
561 (27.5%) individuals. Similarly, correction led to a
better fit of the model predicting PPV (Figure 7)
according to the Hosmer-Lemeshow-Test (uncorrected:
χ2 = 4.5, d.f. = 3, p = 0.211; corrected: χ2 = 2.1, d.f. = 3,
p = 0.558). This was also evident from the reclassifica-
tion table (Table 4), where the ability to classify
individuals into arbitrary groups with “very low” (≤
40%), “low” (> 40% to ≤ 60%), “intermediate” (> 60% to ≤
80%), and “high” (> 80%) PPVs was compared: the uncor-
rected model slightly overestimated PPVs in the “low” and
“intermediate” groups, where observed PPVs were 40%
(instead of > 40%) and 60% (instead of > 60%), respect-
ively. After correction 835 (40.9%) individuals were reclas-
sified; the new classification accurately reflected observed
PPVs within the pre-specified strata (Table 4).0 20 40 60
 0.5  1.0  2.0
20 30 40 50 60
Score
Nasal carriage (%)
PPV (%)
Figure 4 Nomogram describing functional relationship between score
Staphylococcus aureus, and the rapid diagnostic test’s positive predicDiscussion
We describe the derivation and internal validation of a
scoring system able to predict the probability of nasal
MRSA carriage and the expected PPV of a molecular
screening test in admissions to a European tertiary refer-
ral center with low prevalence. In the assessment of ad-
mitted patients published models mainly focus on
measures of discrimination, which summarize the ability
to separate true positive from negative results. Many
models assessed for their discriminatory ability have
been created with the primary aim of restricting
screening efforts to a subset of hospital admissions.
Nevertheless, it seems questionable, if predictive models
can attain high degrees of separation into carriers and
non-carriers at all, as even elaborate models fail to dis-
play acceptable discrimination and thus sensitivity in
detecting unknown carriers when screening is restricted
to a subset of the admitted population. E.g. a recently
published model with comparably good discriminatory
ability (AUC 0.72 in ROC analysis) would have missed
32% of carriers even if 30% of admissions had been
screened [11]. This seems to be an inherent limitation of
prediction tools, since attainable AUCs depend on the
distribution of risk in the population under study; specif-
ically, only rarely encountered distributions displaying
unusually wide spread, such as the uniform or u-formed
distributions, allow AUCs (and with it discriminatory
ability) to surpass values of 0.80 [24]. Given this imper-
fection, it seems futile to continue to design prediction
tools for the sole purpose of suggesting who to screen
on admission.
In addition to discrimination, however, models can be
used for accurate prediction of disease probability, which
is of primary clinical interest for the management or
prevention of disease [24]. As an example, the European
guidelines on cardiovascular disease prevention stress
the importance of absolute risk for the planning of pre-
ventive measures [25]. Similarly, decisions regarding
treatment, e.g. the choice of antibiotic before availability
of cultural results in the presence of clinical infection, or
infection control, e.g. choice of screening method or80 100 120 140 160 180 200
 5.0 10.0 20.0 30.0 40.0 55.0
70 80 90 95 99
, probability of nasal carriage of Methicillin-resistant
tive value.
1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5
−30 −20 −10 0 5 10 15 20 25 30
Prevalence (%)
Correction
Figure 5 Nomogram depicting relationship between prevalence and point values to be added to the score as an adjustment
for prevalence.
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informed by predicted probability of MRSA carriage.
Using a set of potentially readily available predictors
we established a predictive model and transformed its
output into a score ranging from 0 to 200, whereby
predictors were assigned point values in keeping with
the sizes of the adjusted coefficients derived from the lo-
gistic regression model (Table 2). Unlike published
models including factors such as previous antibiotic con-
sumption [11-14,26,27], we have restricted predictors to
a set of unequivocal variables potentially extractable
from the hospital information system on the day of ad-
mission. The advantage of this strategy is that risk as-
sessment would not depend on additional clinician
input, who may have competing priorities, particularly
in busy services [28]. Several authors identified similar
risk factors to the ones in our model including age
[11,14,29-33], nursing home residence [11,14,34,35], and
emergency admission [30,36]. Comparable to the group
of admission diagnoses under the ICD-10-GM headings
“A” (“Certain infections and parasitic diseases”) or “J”
(“Diseases of the respiratory system”), other authors
found certain infections including pneumonia and
wound infections [30], skin and soft tissue infections
[26], skin and bone infection [11], and lung disease [11]Score
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Figure 6 Fit of predictive model in the internal validation
cohort with and without correction. Open circles labeled
“observed” represent probabilities of carriage within intervals
represented by median score. Interval limits were chosen to ensure
equal number of individuals per interval.present at admission significantly associated with MRSA
carrier status. Nevertheless, several groups failed to find
an association between risk factors identified in this
study and MRSA carriage; e.g. Sax et al. did not find a
significant association to nursing home residence or age
> 85 years [13], while Harbarth et al. reported no associ-
ation to admission through the emergency department
[14]. It is difficult to interpret the high prevalence in the
medical emergency department within DC compared to
the rest of the wards; while it refers patients to other
wards, more than 96% of patients in DC and IVD did
not pass through the medical emergency department.
Therefore it seems unlikely, that it filtered MRSA
carriers out before they arrived to other wards. In con-
trast, the particularly low rate in Anesthesiology within
DC (0 of 162, Table 1; 95% CI 0.0% to 2.3% according to
binomial distribution) could have been due to chance, as
prevalence in this unit within IVC (1.6%) did not differ
significantly. Further, we were unable to confirm an in-
dependent influence of sex reported by several groups
[11,14]. These differences likely reflect the inclusion of
comparably weak or setting-specific risk factors; e.g. the
fact that, in the present study, medical emergency ad-
mission had the lowest odds ratio of 1.9 among categor-
ical variables tested and a comparably high p-value of
0.03 (Table 2) may explain why it is rarely reported as
independent predictor in other studies.
Our score showed a useful fit within the DC as shown
graphically (Figure 2) and using the Hosmer-Lemeshow
test on 10 strata. We validated our score on a separate co-
hort (IVC) admitted to wards F, K, L, and M between
August 2008 and January 2012. The prevalence in IVC
compared to DC was lower with 1.7% vs. 2.3%, respect-
ively. The reason for the differing prevalence was mainly
due to lower previous prevalence within wards F, K, L, and
N within DC (1.9%, Table 1). The model’s calibration in
IVC was acceptable as shown by the Hosmer-Lemeshow
-Test on 10 strata, suggesting that the small difference in
prevalence did not necessarily require correction of the
score. Nevertheless, correction resulted in more accurate
fit, evidenced by the lower χ2- value of the Hosmer-
Lemeshow-Test (Figure 6). Furthermore, while both
corrected and uncorrected scores enabled classification of
individuals into strata of increasing carriage probability,
categorization using corrected scores more accurately
Table 3 Classification into probability intervals within validation cohort according to uncorrected and corrected scores
Corrected
[0,1] (1,3] (3,6] (6,100] Observed
uncorr. [0,1] 237 0 0 0 0.0 (0/237)
(1,3] 261 1149 0 0 1.5 (21/1410)
(3,6] 0 261 38 0 1.7 (5/299)
(6,100] 0 0 39 58 8.2 (8/97)
observed 0.4 (2/498) 1.7 (24/1410) 5.2 (4/77) 6.9 (4/58)
Round and square brackets specify values excluded or included, respectively, from the interval.
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tion therefore facilitates use of our models in settings with
different prevalence and thus promotes external validation.
While the presented score correction represents a novel
application in the area of MRSA prediction, its concept is
not new: e.g. adjustment to background rates in cardiovas-
cular risk are commonly applied to achieve accurate pre-
diction, as exemplified by the recalibrated cardiovascular
risk chart for Germany [37].
Apart from its effect on calibration, prevalence differences
greatly affect the PPV of rapid diagnostic tests. Similar to
other reports [16-18] we confirm that a commercial molecu-
lar test based on the amplification of a fragment spanning
SCCmec and orfX has low PPVs in a low prevalence setting.
The substantial proportions (> 66%) of methicillin-
susceptible S. aureus strains lacking mecA among false
positives contributed to this phenomenon. Although the
specificities of the test were almost equal with 98.7% and
98.6% for DC and IVC, respectively, a small difference in
prevalence of 0.6% caused a sizeable drop of PPV from
64.8% (70 of 108) to 54.0% (34 of 63). As higher prevalence
is associated with higher PPV of molecular tests [38], weScore
PP
V
40 50 60 70 80 90 100 110 120 130
0.0
0.2
0.4
0.6
0.8
1.0
observed
uncorrected
corrected
Figure 7 Fit of model predicting the rapid diagnostic test’s
positive predictive value in the validation cohort. Full circles
labeled “observed” represent positive predictive values within
intervals represented by median score. Interval limits were chosen to
ensure equal number of positive results per interval.explored whether individual probability of carriage showed a
similar relationship. Using non-linear regression, we fitted a
function corresponding to the mathematical description
of PPV by specificity, sensitivity, and individual odds
(represented by the score) to observed PPV in eight strata
with different scores (Figure 3). According to the Hosmer-
Lemeshow-Test on a subset of DC with positive molecular
test results, the fit was found acceptable. We then validated
this model on IVC using the Hosmer-Lemeshow-Test on five
strata. The reduction of strata compared to DC was due to
the reduced number of positive results in IVC (in keeping
with lower prevalence and sample size), as we aimed for a
comparable number of positive results in each stratum;
for DC and IVC each stratum thus had an average of
13.5 (108/8) and 12.6 (63/5) positive results, respectively.
The fit was found useful before correction, yet in analogy
to prediction of probability, it was improved after adjust-
ment for prevalence. This was also evident from the re-
classification tables, which demonstrated a more accurate
categorization into pre-specified strata. Hence, in addition
to the prediction of probability of carriage, our model also
predicted the expected PPV of a rapid test for a given
individual.
The score can be derived in external settings from a
set of patient parameters (containing information on
age, nursing home residence, emergency admission, and
admission diagnosis) in two steps: 1) an initial score is
calculated by substracting 10 from the age and further
adding scores according to column “Score” in Table 2;
2) if external MRSA prevalence differs from 2.3% (preva-
lence of DC), a correction score, derivable from the
nomogram in Figure 5 according to prevalence, has to be
added to the initial score. The resulting final score can
then be translated into probability of carriage and
expected PPV using the nomogram in Figure 4. Probabil-
ity of carriage can inform several clinical decisions. Em-
piric treatment in case of e.g. wound infections could
include antibiotics suitable against MRSA if high prob-
ability of carriage is likely (e.g. ≥ 6%); also, preemptive
isolation or further control measures could be automatic-
ally carried out in these cases. Further, the prediction of
PPV could help target molecular tests to individuals
where equivocal results are unlikely. Clearly, the
Table 4 Prediction of intervals of a rapid diagnostic test’s expected positive predictive value within the validation
cohort according to uncorrected and corrected scores
Corrected
[0,40] (40,60] (60,80] (80,100] Observed
uncorr. [0,40] 173 0 0 0 0.0 (0/4)
(40,60] 226 520 0 0 40.0 (8/20)
(60,80] 0 584 433 0 60.0 (18/30)
(80,100] 0 0 25 82 88.9 (8/9)
observed 25.0 (2/8) 47.1 (16/34) 71.4 (10/14) 85.7 (6/7)
Round and square brackets specify values excluded or included, respectively, from the interval. Values in parentheses in row and column labeled “observed”
represent quotients of true positives divided by all positives within the interval.
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tests should be applied is a matter of taste; we propose
that rapid diagnostic testing be restricted to individuals
with expected PPV over 80%, and that cultural screening
be used for the rest of admissions. For IVC, this thresh-
old would include only 4.0% of individuals.
Our study has several limitations. In contrast to
reports with screening compliance exceeding 80%
[11,13,14,29,30], only 61% of eligible patients had been
screened correctly in our derivation cohort. This was
due to the high number of patients that had to be
excluded due to testing of sites other than the nose and
tests taken more than 2 days after admission. While in-
complete coverage of patients may have introduced a
bias, the models generated from DC still performed fa-
vorably in a separate cohort (IVC). Also, the internal val-
idation cohort consisted of a convenience sample
retrospectively extracted from a subset of wards that co-
incidentally pilot-tested an electronic nursing history
system during different periods after August 2008. The
different sampling method may have decreased compar-
ability between DC and IVC. Specifically, it remains un-
known, why age was different between the two cohorts.
Increased age in IVC may have been due to demo-
graphic changes within the admitted patients, as the pro-
portion of males remained the same (even when
compared to wards F, K, L, M in DC), and increase of
age was not associated with increased prevalence, as
might have been expected in the case of selective inclu-
sion of older patients. The use of ICD-10-GM admission
diagnoses might also have introduced a bias, since the
degree of inter-rater agreement in coding admission diag-
noses is not well established. Nevertheless, it is conceivable
that agreement on ICD-10 chapter headings, as used in our
study, will be reasonably high even between raters in differ-
ent countries. Also, availability of coded admission diagno-
ses within the first day of admission may pose a hindrance
for the use of our models: in our center, only 49% and 66%
of admission diagnoses were available in IVC as ICD-10
-GM codes on the day of admission and one day after ad-
mission, respectively; thus, speedy coding of admissiondiagnoses (alternatively of chapter headings) has to be
implemented for the automated use of our models. Never-
theless, as the most authorative classification of diseases,
the choice of ICD-10-GM seems natural; further research
could elucidate, whether codes including U80.0 (S. aureus
with methicillin or other resistance), Z22.3 (carrier of
staphylococci or other bacteria), or Z29.0 (isolation)
predicts MRSA carriage. While neither diagnosis was coded
as admission diagnosis in our cohorts, the previous use of
these codes as secondary diagnoses may well be predictive;
nevertheless, this would require that coding data from
other hospitals be made available to the admitting center.
Finally, our sample size was rather small for a low preva-
lence area with 3091 and 2043 individuals, respectively; this
likely decreased our power to find weak associations be-
tween predictors and MRSA carriage. Despite these
limitations, we were able to derive and internally validate a
scoring system that can be used both for the prediction of
individual probability of carriage and the expected positive
predictive value of a rapid diagnostic test. Due to the use of
unequivocal and readily available predictors, a completely
automated use of our model is conceivable. Future work
will focus on the external validation of our model using
data from different European hospitals.
Conclusions
The presented models can be used to accurately predict
the probability of nasal carriage of MRSA and the
expected PPV of a commercial molecular test. Model
output can be used to inform a variety of clinically relevant
decisions including empiric treatment of infections
(e.g. choice of antibiotics), infection control (e.g. prompting
of preemptive isolation), and choice of screening method
(e.g. by restricting rapid tests to indiviudals with expected
PPV ≥ 80%). The use of unequivocal predictors potentially
permits automated scoring of data extracted from existing
hospital information systems.
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